The annual J.P. Morgan Healthcare Conference, often called the Superbowl of biotech, kicked off on January 9, 2017.
The Motley Fool has you covered with reports on company presentations and themes from the conference. Check back daily for updates!
- 3 Things We Might See From Illumina Next Week
- Why AMAG Pharmaceuticals, Inc. Is Falling Today
- Is Celgene Simply the Best Biotech Stock on the Planet?
- 4 Things Gilead Sciences' CEO Says to Expect in 2017
- 5 Ways Vertex Pharmaceuticals Plans to Grow in 2017 and Beyond
- Incyte's Prospects Get Even Brighter With Merck Announcement
- 3 Big Reasons (and 8 Smaller Ones) to Buy Ionis Pharmaceuticals Stock
- Here's Why Illumina Is Soaring Today
- What Sarepta Therapeutics' CEO Said That Made the Stock Soar
- What's Next For Celgene
- Johnson & Johnson CEO's Fireside Chat: 5 Things You Need to Know
- 3 Charts Every Bristol-Myers Squibb Shareholder Needs to See
- Is This Going To Be Sarepta Therapeutics' Year?
- Valeant Pharmaceuticals: Separating Fact From Fiction
- 3 Surprises From Pfizer at the J. P. Morgan Healthcare Conference
- 7 Reasons AbbVie's Stock Could Soar in 2017
- It's Full Speed Ahead for Opko Health After Pipeline Stumble
- Why Exact Sciences' Stock Could Go Much Higher
- Illumina Lights It Up
PS -- if you're interested in checking out how much things have changed since this time in 2016, here's last year's landing page.
The Motley Fool owns shares of and recommends Celgene, Gilead Sciences, Illumina, Ionis Pharmaceuticals, and Valeant Pharmaceuticals. The Motley Fool recommends Johnson and Johnson and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.